Discovery of a Novel Trifunctional Inhibitor for B Cell Driven Diseases

• Trifunctional target inhibition to address the root causes of B cell-driven diseases

• Engineering best-in-class pH-dependent binding to FcRn for clearance of IgG and extended 1/2-life

Speakers:

Julian Chandler

Associate Director

Alexion, AstraZeneca Rare Disease